Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05358938 · ClinicalTrials.gov registry record · Early Phase 1
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
A Early Phase 1 study of Cutaneous Melanoma and Merkel Cell Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05358938: Active Early Phase 1 study of Cutaneous Melanoma and Merkel Cell Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05358938 is a Early Phase 1 study of Cutaneous Melanoma and Merkel Cell Carcinoma that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 22 participants, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05358938, a Early Phase 1 study of Cutaneous Melanoma and Merkel Cell Carcinoma, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
Primary Outcome
Proportion of patients approached who consent to participate in study, and investigators will determine the 95% confidence interval
Conditions Studied
Interventions
- OTHER Exercise
- DRUG Checkpoint Blockade, Immune
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2026-08 |
| Phase | Early Phase 1 |
What the registry record for NCT05358938 still lists
NCT05358938 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Exercise is the first listed.
NCT05358938 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05358938 about?
NCT05358938 is a clinical study titled "Exercise to Boost Response to Checkpoint Blockade Immunotherapy". 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
What is the current status of trial NCT05358938?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2022-06-21. Estimated completion is 2026-08.
What conditions does trial NCT05358938 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05358938?
The interventions under investigation include: Exercise (OTHER), Checkpoint Blockade, Immune (DRUG).
Who is sponsoring clinical trial NCT05358938?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05358938 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05358938's enrollment target sits among peer trials
22 24th of 30 higher than 7 of 30 other Cutaneous Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
ACTengine® IMA203 Combined With mRNA-4203
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI